Every report comes from a Lived member, sent anonymously.
Have you tried Singulair (Montelukast) for Asthma?
Montelukast, sold under the brand name Singulair and as a generic, is a once-daily prescription medicine taken by mouth for asthma and allergies. It is approved to prevent asthma symptoms and for long-term asthma control in adults and children 12 months and older, and to prevent exercise-induced bronchoconstriction (narrowing of the airways triggered by exercise) in people 6 and older. It also relieves nasal allergy symptoms, also called allergic rhinitis: seasonal allergies such as hay fever from age 2, and year-round indoor allergies from 6 months. It belongs to a group of medicines called leukotriene receptor antagonists. For persistent asthma, a daily inhaled corticosteroid (a steroid inhaler) controls symptoms better and prevents more flare-ups than montelukast does when either is used alone, so inhaled steroids remain the preferred first choice. Montelukast is used as an alternative when an inhaled steroid is not suitable, or added to one when the inhaler alone is not enough. For nasal allergies, the US Food and Drug Administration (FDA) advises reserving montelukast for people whose symptoms are not controlled by, or who cannot tolerate, other allergy medicines such as antihistamines and steroid nasal sprays. That restriction comes from its boxed warning about mood and behavior changes, described under Side Effects.
Leukotrienes are chemical messengers released by immune cells, such as mast cells and eosinophils, during allergic and asthmatic reactions. In the lungs they tighten the muscle around the airways, cause swelling of the airway lining and help keep inflammation going. In the nose, they are released after contact with an allergen and contribute to congestion and other allergy symptoms. Montelukast attaches to the receptor these leukotrienes normally act on and blocks it, so they have less effect. It works as a preventer taken every day. It does not quickly open the airways during an asthma attack, which is why it cannot replace a rescue inhaler.
Montelukast is taken once a day, with or without food. The form depends on age: adults and teenagers 15 and older take a 10 mg tablet, children 6 to 14 take a 5 mg chewable tablet, children 2 to 5 take a 4 mg chewable tablet or a packet of 4 mg granules, and younger children approved for it take the 4 mg granules. For asthma it is taken in the evening. For allergies alone, the timing can suit the person. Someone with both asthma and allergies takes a single dose in the evening, not one for each condition. The granules can go straight into the mouth or be mixed with a spoonful of cold or room-temperature applesauce, carrots, rice or ice cream, or with a teaspoon of baby formula or breast milk. Open the packet only when ready, and give the full dose within 15 minutes. To prevent exercise-induced symptoms, a single dose is taken at least 2 hours before exercise, and no second dose within 24 hours. People who already take montelukast every day should not take an extra dose before exercise. If a daily dose is missed, take the next one at the usual time rather than taking two together. For asthma, keep taking it every day, including when you feel well and during flare-ups, and continue other asthma medicines unless the prescriber changes them. Because montelukast does not relieve an asthma attack, a short-acting rescue inhaler (the quick-relief inhaler used when symptoms start) should always be available.
In clinical trials, the side effects reported most often were upper respiratory infections, fever, headache, sore throat, cough, stomach pain, diarrhea and ear infections. Several of these were nearly as common in people taking a placebo; headache, for example, affected about 18 percent of adults on either. Montelukast carries an FDA boxed warning, the agency's most prominent warning, about serious mood and behavior changes. Reported problems include agitation or aggression, anxiety, depression, trouble sleeping, vivid or disturbing dreams, sleepwalking, confusion, attention or memory problems, hallucinations, stuttering, tremor, and suicidal thoughts and actions, including suicide. They have occurred in adults, teenagers and children, with and without a history of mental health problems, mostly during treatment but sometimes after stopping. How often they happen and who is most at risk is not well understood. If you or a child taking montelukast has new mood, behavior or thinking changes that are unusual for that person, stop the medicine and contact the prescriber right away. In many reported cases symptoms went away after stopping, but in some they lasted longer and needed continued care. The FDA asks both patients and caregivers to watch for these changes, since a child may not describe them.
Montelukast has few drug interactions that change how it is used. Its label lists no dose adjustment with common medicines such as prednisone, birth control pills, warfarin (a blood thinner) and thyroid hormone. Still, the prescriber and pharmacist should know everything you take. Do not replace an inhaled or oral steroid with montelukast on your own. A steroid dose can sometimes be lowered gradually under medical supervision, but montelukast should not be substituted for it abruptly. Rarely, people with asthma taking montelukast have developed a condition with high levels of eosinophils (a type of white blood cell) and inflammation of blood vessels, sometimes while oral steroids were being reduced; whether montelukast causes it is not established. A new rash, numbness or tingling in the hands or feet, or worsening breathing during a steroid taper should be reported to the prescriber. People whose asthma is triggered by aspirin should keep avoiding aspirin and anti-inflammatory pain relievers such as ibuprofen and naproxen. Montelukast can improve their breathing overall, but it has not been shown to prevent a reaction to these drugs. The 4 mg and 5 mg chewable tablets contain aspartame, a source of phenylalanine. This matters for people with phenylketonuria (PKU), an inherited condition in which the body cannot break down phenylalanine. Studies spanning decades of use in pregnancy have not linked montelukast to major birth defects, although those studies have limitations, and poorly controlled asthma itself raises risks for mother and baby. Montelukast passes into breast milk; available data do not suggest a significant risk to breastfed infants.
In adult trials, montelukast's effect on asthma symptoms, rescue inhaler use and peak flow (a home measure of how fast you can blow air out) appeared after the first dose and lasted through the 24 hours between doses. As a daily controller, its value shows with steady use: fewer daytime symptoms, fewer nights woken by asthma and less need for the rescue inhaler. Taking more than the standard dose has not added benefit for adults. Needing the rescue inhaler more often than usual, or more puffs in a day than prescribed, is a sign that asthma is not well controlled and is a reason to contact the care team. It may mean the overall treatment plan needs to change. Because of the boxed warning, the FDA asks prescribers to weigh benefits and risks both when starting montelukast and when deciding whether to continue it. It is reasonable to revisit whether you still need it, especially for allergies, where many alternatives exist. If it was stopped because of mood or behavior changes, restarting it is a decision to make carefully with the prescriber.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Singulair (Montelukast), what you've noticed, or ask the community a question.